Skip to content
Calculator
Compare

Peptide comparisons

Last updated: October 2, 2026 · 1 min read · By the Grey Peptides Editorial Board

A digital glass bathroom scale with a blue tape measure resting on it
Photo by Pixabay on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • Every table cell is read from the encyclopedia entry for that compound; nothing is scored or ranked.
  • Each analysis cites the trials it uses, and head-to-head trials are named where they exist.

Comparisons

  • Cagrilintide vs pramlintide: Cagrilintide and pramlintide side by side: two amylin analogs, one an approved mealtime diabetes injection and one a weekly obesity drug still in trials.
  • Orforglipron vs oral semaglutide: Orforglipron and oral semaglutide side by side: a small-molecule GLP-1 pill against a peptide tablet, and the ACHIEVE-3 trial that compared them directly.
  • Semaglutide vs liraglutide: Semaglutide and liraglutide side by side: the head-to-head trials for weight and diabetes, the heart-outcome trials, and why one is weekly and the other daily.
  • Survodutide vs mazdutide: Survodutide and mazdutide side by side: two drugs that act on both the GLP-1 and glucagon receptors, their trial results, and where each stands on approval.

Frequently asked questions

How are these comparisons built?

The table is drawn from our dataset, the same fields the encyclopedia entries print, and the analysis below it cites each trial it relies on.

Sources

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All comparisons

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead